ATE.v/ATBPF +.04 to C$.32 Antibe closed a licensing deal with a pharma in South Korea. This is part of their strategy, signing licensing deals in non major markets to provide upfront cash while retaining the licensing to the all important North American and European markets for a potential big pharma partner.
Antibe gets 1.3 million cash up front and double digit fees once the product is developed and sold in S Korea.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.